natgillin/translations-raw huggingface dataset:
Gross recoveries received during the period.
Znesek, določen s prvotno cenitvijo
Delinquencies 30-59 Days %
Cenitev sredstva ob nastanku zakupa.
Based upon total balance of receivables, not number of accounts (%).
Način prvotne cenitve
Delinquencies 60-89 Days %
Način cenitve ob nastanku zakupa.
Delinquencies 90-119 Days %
Datum prvotne cenitve
Delinquencies 120-149 Days %
Datum cenitve sredstva ob nastanku.
Delinquencies 150-179 Days %
Posodobljena cenitev sredstva
Delinquencies 180+ Days %
Zadnja cenitev sredstva.
Dilutions
Posodobljeni način cenitve
Total reductions in principal receivables during the period, i.e. inclusive of fraud claims.
Način cenitve na datum najnovejše cenitve.
Revenue Collections In The Period
Posodobljen datum cenitve
Collections treated as revenue in the period.
Datum zadnje cenitve sredstva.
Principal Collections In The Period
Če od nastanka zakupa cenitev ni bila posodobljena, navedite datum prvotne cenitve.
Collections treated as principal in the period.
Kumulativna bruto neplačila – skupina
Any Trigger Occurrence
Vsota vseh izterjav od konca obdobja, v znesku v valuti.
Has any trigger event occurred, that is still outstanding? e.g. any pay-out event, any trigger based upon the originator’s rating, status or value of delinquencies, yield, dilutions, defaults etc.
Referenčni indeks obrestne mere, kot je opredeljen v ponudbenem dokumentu, ki se uporablja za zadevno posebno tranšo obveznice.
SPV Size - Value
PRILOGA VIII
Face value of all receivables (principal and charges) in which the trust or SPV has a beneficial interest at the cut-off date.
Poročila vlagateljev
SPV Size - Number Of Accounts
Poročila vlagateljev vsebujejo informacije o:
Number of accounts in which the trust or SPV has a beneficial interest at the cut-off date.
rezultatih sredstev;
SPV Size - Value - Principal Only
podrobni porazdelitvi denarnih tokov;
Face value of all receivables (principal only) in which the trust or SPV had a beneficial interest at the cut-off date.
seznamu vseh sprožilcev posla in njihovem statusu;
Note Balance
seznamu vseh nasprotnih strank v poslu, njihovi vlogi in njihovih bonitetnih ocenah;
Face value of all asset-backed notes, collateralised by the receivables in the trust or SPV.
podrobnostih o denarnih sredstvih, ki sta jih v posel vložila originator/sponzor, ali kateri drugi podpori poslu, vključno s črpanjem ali koriščenjem likvidnostnega kredita ali kreditno podporo in podporo, ki jo zagotovi tretja stranka;
Transferor Interest %
pozitivnem stanju kredita pogodbe o zajamčeni naložbi in na drugih bančnih računih;
The actual transferor’s interest in the trust, expressed as a percentage.
podrobnostih morebitnih zamenjav (npr. stopnje, plačila in hipotetični zneski) in drugih pogodbah o varovanju pred tveganjem v zvezi s poslom, vključno z vsemi povezanimi instrumenti zavarovanja plačil;
Excess Spread Amount
opredelitvah ključnih pojmov (kot so neredna plačila, neplačila in predčasna plačila);
The amount remaining after note interest and topping up of any reserve account.
kodi LEI, kodi ISIN in vseh drugih identifikacijskih kodah finančnega premoženja ali kodah za identifikacijo izdajatelja in strukturiranega finančnega instrumenta;
Series Level Information (For master trusts only)
kontaktnih podatkih subjekta, ki pripravlja poročilo vlagatelja.
Series Name
Ta uredba bi se zato morala uporabljati od 1. januarja 2017.
Name of series, if part of a master trust.
ESMA bi morala potrebna tehnična navodila glede poročanja sporočiti pravočasno pred začetkom uporabe te uredbe.
Investor Interest For This Series At End Of Period %
Zaostala plačila se opredelijo kot:
The investor’s interest of this series in the trust, expressed as a percentage.
skupna dosedanja zapadla plačila MINUS skupna dosedanja prejeta plačila MINUS kapitalizirani zneski.
Revenue Allocated To This Series
Podrobnosti o datumu plačila
Revenue amounts allocated to this series from the trust.
Datum plačila kredita
The amount remaining after the period’s collections have been fully applied to cover the issuer’s obligations per the revenue waterfall in the transaction documentation.
Datum odprave kršitve.
Telephone number and email address.
Če je kršitev več, datum odprave zadnje kršitve.
Tranche Level Information (For this series only)
Znesek zaostalih plačil glavnice
The designation (typically a letter and/or number) given to a tranche of bonds which exhibit the same rights, priorities and characteristics as defined in the prospectus, e.g. 2012 Class A1a etc.
skupna dosedanja zapadla plačila glavnice MINUS skupna dosedanja prejeta plačila glavnice MINUS kapitalizirani zneski.
The base reference interest index as defined in the prospectus or final terms applicable to this specific tranche.
Ali je prišlo do kakega sprožilnega dogodka, ki je še vedno neporavnan?
Date this bond was issued.
Na primer dogodek izplačila, sprožilec na podlagi bonitetne ocene, statusa ali vrednosti nerednih plačil, donosa, zmanjšanj vrednosti, neplačil originatorja itd.
The frequency with which interest is due to be paid on this specific tranche.
skupna dosedanja zapadla plačila MINUS skupna dosedanja prejeta plačila MINUS kapitalizirani zneski.
Series name
Datum prejetja zadnje knjige dohodkov od najemnin/seznama zapolnjenosti nepremičnine (pri nepremičninah za gostinstvo (hoteli) in zdravstveno nego uporabite povprečno zasedenost za obdobje, za katero se sporočijo finančni izkazi).
If standalone, use Pool Identifier.
Poštna številka nepremičnine
Commission Implementing Regulation (EU) 2015/4
Izvedbena uredba Komisije (EU) 2015/4
of 5 January 2015
z dne 5. januarja 2015
Done at Brussels, 5 January 2015.
V Bruslju, 5. januarja 2015
amending Annex I to Regulation (EC) No 443/2009 of the European Parliament and of the Council in order to take into account the evolution of the mass of new passenger cars registered in 2011, 2012 and 2013
o spremembi Priloge I k Uredbi (ES) št. 443/2009 Evropskega parlamenta in Sveta, da se upoštevajo spremembe mase novih osebnih avtomobilov, registriranih v letih 2011, 2012 in 2013
Having regard to Regulation (EC) No 443/2009 of the European Parliament and of the Council of 23 April 2009 setting emission performance standards for new passenger cars as part of the Community's integrated approach to reduce CO2 emissions from light-duty vehicles [1], and in particular Article 13(2) thereof,
ob upoštevanju Uredbe (ES) št. 443/2009 Evropskega parlamenta in Sveta z dne 23. aprila 2009 o določitvi standardov emisijskih vrednosti za nove osebne avtomobile kot del celostnega pristopa Skupnosti za zmanjšanje emisij CO2 iz lahkih tovornih vozil [1] in zlasti člena 13(2) Uredbe,
The average mass value used for the purpose of calculating the specific emissions of CO2 for each new passenger car is to be adjusted every three years to take into account any changes in the average mass of the new vehicles registered in the Union.
Povprečno masno vrednost, ki se uporabi za izračun specifičnih emisij CO2 za vsak nov osebni avtomobil, je treba prilagoditi vsaka tri leta, da se upoštevajo morebitne spremembe povprečne mase novih vozil, registriranih v Uniji.
It is evident from the monitoring of the mass in running order of new passenger cars registered in calendar years 2011, 2012 and 2013 that the average mass has increased and that the figure M0 referred to in point 1(b) of Annex I to Regulation (EC) No 443/2009 should therefore be adjusted.
Iz spremljanja mase neobremenjenih novih osebnih avtomobilov, registriranih v koledarskih letih 2011, 2012 in 2013, je razvidno, da se je povprečna masa povečala in da bi bilo zato treba vrednost M0 iz točke 1(b) Priloge I k Uredbi (ES) št. 443/2009 prilagoditi.
Exceptionally for this first adjustment, it is appropriate to take into account that the quality of the data monitored in the years 2011, 2012 and 2013 has differed.
Za to prvo prilagoditev je izjemoma primerno upoštevati, da je kakovost podatkov, ki so se spremljali v letih 2011, 2012 in 2013, različna.
The new value should therefore be determined by taking into account only those mass values that it has been possible to verify by the manufacturers concerned, whilst excluding values from the calculation that were obviously incorrect, i.e. values exceeding 2840 kg or lower than 500 kg as well as values relating to vehicles that did not fall within the scope of Regulation (EC) No 443/2009.
Novo vrednost bi bilo zato treba določiti ob upoštevanju samo tistih masnih vrednosti, ki so jih zadevni proizvajalci lahko preverili, očitno napačne vrednosti, tj. vrednosti, ki so večje od 2840 kg ali manjše od 500 kg, ter vrednosti, ki se nanašajo na vozila zunaj področja uporabe Uredbe (ES) št. 443/2009, pa bi bilo treba izločiti iz izračuna.
The new value is moreover based on the weighted average taking into account the number of new registrations in each of the reference years.
Nova vrednost poleg tega temelji na tehtanem povprečju, ob upoštevanju števila novih registracij v vsakem referenčnem letu.
Against that background, the M0 value to be applied from 1 January 2016 should be increased by 20,4 kg from 1372,0 to 1392,4,
Glede na navedeno bi bilo treba vrednost M0, ki jo je treba uporabljati od 1. januarja 2016, povečati za 20,4 kg, in sicer s 1372,0 na 1392,4 –
From 2016:
Specifične emisije CO2 = 130 + a × (M – M0)
Specific emission of CO2 = 130 + a × (M – M0)
kjer:
Where:
M masa vozila v kilogramih (kg)
M mass of the vehicle in kilograms (kg)
a 0,0457“
a 0,0457’
Člen 2
This Regulation shall be binding in its entirety and directly applicable in all Member States.
V Bruslju, 31. oktobra 2014
Done at Brussels, 31 October 2014.
Za Komisijo
OJ L 140, 5.6.2009, p.
Točka 1(b) Priloge I k Uredbi (ES) št. 443/2009 se nadomesti z naslednjim:
authorising a health claim made on foods, other than those referring to the reduction of disease risk and to children's development and health and amending Regulation (EU) No 432/2012
o odobritvi zdravstvene trditve na živilih, razen tistih, ki se nanašajo na zmanjšanje tveganja za nastanek bolezni ter na razvoj in zdravje otrok, in o spremembi Uredbe (EU) št. 432/2012
Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods [1], and in particular Article 18(4) thereof,
ob upoštevanju Uredbe (ES) št. 1924/2006 Evropskega parlamenta in Sveta z dne 20. decembra 2006 o prehranskih in zdravstvenih trditvah na živilih [1] ter zlasti člena 18(4) Uredbe,
Regulation (EC) No 1924/2006 provides that health claims made on foods are prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims.
Uredba (ES) št. 1924/2006 določa, da so zdravstvene trditve na živilih prepovedane, razen če jih Komisija v skladu z navedeno uredbo odobri in uvrsti na seznam dovoljenih trditev.
Pursuant to Article 13(3) of Regulation (EC) No 1924/2006, Commission Regulation (EU) No 432/2012 [2] was adopted, which established a list of permitted health claims made on foods other than those referring to the reduction of disease risk and to children's development and health.
V skladu s členom 13(3) Uredbe (ES) št. 1924/2006 je Komisija sprejela Uredbo (EU) št. 432/2012 [2] o seznamu dovoljenih zdravstvenih trditev na živilih, razen trditev, ki se nanašajo na zmanjšanje tveganja za nastanek bolezni ter na razvoj in zdravje otrok.
Regulation (EC) No 1924/2006 also provides that applications for authorisations of health claims are to be submitted by food business operators to the national competent authority of a Member State.
Uredba (ES) št. 1924/2006 določa tudi, da morajo nosilci živilske dejavnosti vloge za odobritev zdravstvenih trditev vložiti pri pristojnem nacionalnem organu države članice.
The Commission is to decide on the authorisation of health claims taking into account the opinion delivered by the Authority.
Komisija ob upoštevanju mnenja Agencije sprejme odločitev o odobritvi zdravstvenih trditev.
In order to stimulate innovation, health claims which are based on newly developed scientific evidence and/or which include a request for the protection of proprietary data should undergo an accelerated type of authorisation.
Zaradi spodbujanja inovacij bi bilo treba zdravstvene trditve, ki temeljijo na novo ugotovljenih znanstvenih dokazih in/ali vključujejo zahtevo za zakonsko zaščito podatkov, odobriti po hitrem postopku.
Following an application from Aptonia, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to glycaemic carbohydrates and recovery of normal muscle function (contraction) after strenuous exercise (Question No EFSA-Q-2013-00234) [3].
Družba Aptonia je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z glikemičnimi ogljikovimi hidrati in obnovo normalnega delovanja mišic (krčenje) po naporni telesni aktivnosti (vprašanje št.
The claim proposed by the applicant was worded as follows: ‘Glycaemic carbohydrates increase muscle glycogen repletion following strenuous exercise’.
EFSA-Q-2013-00234) [3].
On 25 October 2013, the Commission and the Member States received the scientific opinion from the Authority which concluded that on the basis of the data presented, a cause and effect relationship had been established between the consumption of glycaemic carbohydrates and the claimed effect.
Vložnik je predlagal naslednjo trditev: „Glikemični ogljikovi hidrati pospešijo obnovo glikogena v mišicah po naporni telesni aktivnosti.“
Accordingly, a health claim reflecting this conclusion should be considered as complying with the requirements of Regulation (EC) No 1924/2006 and should be included in the Union list of permitted claims, established by Regulation (EU) No 432/2012.
Komisija in države članice so 25. oktobra 2013 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da je vzročno-posledična povezava med uživanjem glikemičnih ogljikovih hidratov in navedeno trditvijo utemeljena.
One of the objectives of Regulation (EC) No 1924/2006 is to ensure that health claims are truthful, clear and reliable and useful to the consumer, and that the wording and the presentation are taken into account in that respect.
Zdravstveno trditev, ki odraža to ugotovitev, bi zato bilo treba šteti za skladno z zahtevami iz Uredbe (ES) št. 1924/2006 in jo uvrstiti na seznam dovoljenih trditev Unije, uveden z Uredbo (EU) št. 432/2012.
Therefore, where the wording of claims used by the applicant has the same meaning for consumers as that of an authorised health claim, because they demonstrate the same relationship that exists between a food category, a food or one of its constituents and health, they should be subject to the same conditions of use as those listed in the Annex to this Regulation.
Eden od ciljev Uredbe (ES) št. 1924/2006 je zagotoviti, da so zdravstvene trditve resnične, jasne, zanesljive in uporabne za potrošnika ter da se pri tem upoštevata besedilo in predstavitev trditve.
In accordance with Article 20 of Regulation (EC) No 1924/2006, the Register of nutrition and health claims containing all authorised health claims should be updated in order to take into account this Regulation.
Kadar ima besedilo trditev, ki ga uporabi vložnik, za potrošnike enak pomen kot odobrena zdravstvena trditev, ker predstavljata isto povezavo med kategorijo živila, živilom ali njegovo sestavino in zdravjem, bi bilo treba te trditve uporabljati pod enakimi pogoji uporabe, kot so navedeni v Prilogi k tej uredbi.
The comments from the applicant and the members of the public received by the Commission pursuant to Article 16(6) of Regulation (EC) No 1924/2006 have been considered when setting the measures provided for in this Regulation.
V skladu s členom 20 Uredbe (ES) št. 1924/2006 bi bilo treba register prehranskih in zdravstvenih trditev, ki vsebuje vse odobrene zdravstvene trditve, posodobiti, da se upošteva ta uredba.
Regulation (EU) No 432/2012 should therefore be amended accordingly.
Pri določanju ukrepov iz te uredbe so bile upoštevane pripombe, ki so jih vložnik in predstavniki javnosti poslali Komisiji v skladu s členom 16(6) Uredbe (ES) št. 1924/2006.
The Member States have been consulted,
Uredbo (EU) št. 432/2012 bi bilo zato treba ustrezno spremeniti.
HAS ADOPTED THIS REGULATION:
Opravljeno je bilo posvetovanje z državami članicami –
The health claim set out in the Annex to this Regulation shall be included in the Union list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.
Člen 1
Article 2
Zdravstvena trditev iz Priloge k tej uredbi se uvrsti na seznam dovoljenih trditev Unije v skladu s členom 13(3) Uredbe (ES) št. 1924/2006.
The Annex to Regulation (EU) No 432/2012 is amended in accordance with the Annex to this Regulation.
Člen 2
Article 3
Priloga k Uredbi (EU) št. 432/2012 se spremeni v skladu s Prilogo k tej uredbi.
Done at Brussels, 6 January 2015.
Ta uredba je v celoti zavezujoča in se neposredno uporablja v vseh državah članicah.
For the Commission
V Bruslju, 6. januarja 2015
OJ L 404, 30.12.2006, p. 9.
Predsednik
In the Annex to Regulation (EU) No 432/2012, the following entry is inserted in an alphabetical order:
V Prilogo k Uredbi (EU) št. 432/2012 se po abecednem redu vstavi naslednji vnos:
Carbohydrates contribute to the recovery of normal muscle function (contraction) after highly intensive and/or long-lasting physical exercise leading to muscle fatigue and the depletion of glycogen stores in skeletal muscle
Ogljikovi hidrati prispevajo k obnovi normalnega delovanja mišic (krčenje) po zelo intenzivni in/ali dolgotrajni telesni aktivnosti, ki povzroča utrujenost mišic in izčrpanje zalog glikogena v skeletnih mišicah.
The claim may be used only for food which provides carbohydrates which are metabolised by humans (excluding polyols).
Trditev se lahko uporablja le za živilo, ki zagotavlja ogljikove hidrate, ki jih lahko človek presnavlja (razen poliolov).
Information shall be given to the consumer that the beneficial effect is obtained with the consumption of carbohydrates, from all sources, at a total intake of 4 g per kg body weight, at doses, within the first 4 hours and no later than 6 hours, following highly intensive and/or long-lasting physical exercise leading to muscle fatigue and the depletion of glycogen stores in skeletal muscle.
Potrošnike je treba obvestiti, da se koristni učinek doseže z uživanjem ogljikovih hidratov iz vseh virov s skupnim vnosom 4 g na kg telesne teže, v odmerkih v prvih 4 urah in najpozneje 6 ur po zelo intenzivni in/ali dolgotrajni telesni aktivnosti, ki povzroča utrujenost mišic in izčrpanje zalog glikogena v skeletnih mišicah.
The claim may be used only for foods intended for adults who have performed highly intensive and/or long-lasting physical exercise leading to muscle fatigue and the depletion of glycogen stores in skeletal muscle.
Trditev se lahko uporablja le za živila, namenjena odraslim po zelo intenzivni in/ali dolgotrajni telesni aktivnosti, ki povzroča utrujenost mišic in izčrpanje zalog glikogena v skeletnih mišicah.
In some cases, the scientific risk assessment alone cannot provide all the information on which a risk management decision should be based and therefore other legitimate factors relevant to the matter under consideration should also be taken into account.
V nekaterih primerih znanstvena ocena tveganja sama ne more zagotoviti vseh informacij, na katerih bi morala temeljiti odločitev o obvladovanju tveganja, temveč bi bilo treba upoštevati druge zakonite dejavnike, ki so pomembni za obravnavano zadevo.
Following an application from Dextro Energy GmbH & Co.
Družba Dextro Energy GmbH & Co.
KG, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to glucose and contribution to energy-yielding metabolism (Question No EFSA-Q-2012-00266) [2].
KG je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z glukozo in prispevanjem k sproščanju energije pri presnovi (vprašanje št.
On 11 May 2012, the Commission and the Member States received the scientific opinion from the Authority which concluded that on the basis of the data presented, a cause and effect relationship had been established between the consumption of glucose and contribution to energy-yielding metabolism.
Vložnik je predlagal naslednjo trditev: „Glukoza se presnavlja v telesu v procesih normalne energijske presnove.“
The target population is the general population.
Komisija in države članice so 11. maja 2012 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da je vzročno-posledična povezava med uživanjem glukoze in prispevanjem k sproščanju energije pri presnovi utemeljena.
Following an application from Dextro Energy GmbH & Co.
Ciljna populacija je splošno prebivalstvo.
KG, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to glucose and contribution to energy-yielding metabolism (Question No EFSA-Q-2012-00267) [3].
Družba Dextro Energy GmbH & Co.
The claim proposed by the applicant was worded as follows: ‘Glucose supports normal physical activity’.
KG je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z glukozo in prispevanjem k sproščanju energije pri presnovi (vprašanje št.
Following an application from Dextro Energy GmbH & Co.
Vložnik je predlagal naslednjo trditev: „Glukoza podpira normalno telesno aktivnost.“
KG, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to glucose and contribution to energy-yielding metabolism (Question No EFSA-Q-2012-00268) [4].
Komisija in države članice so 11. maja 2012 prejele znanstveno mnenje Agencije, ki je ugotovila, da je bila trditev o glukozi in prispevanju k sproščanju energije pri presnovi že pozitivn o ocenjena, in se sklicevala na svoje mnenje o zdravstveni trditvi v zvezi z glukozo in prispevanjem k sproščanju energije pri presnovi (vprašanje št.
The claim proposed by the applicant was worded as follows: ‘Glucose contributes to normal energy-yielding metabolism’.
EFSA-Q- 2012-00266).
KG, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to glucose and contribution to energy-yielding metabolism (Question No EFSA-Q-2012-00269) [5].
KG je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z glukozo in prispevanjem k sproščanju energije pri presnovi (vprašanje št.
Following an application from Dextro Energy GmbH & Co.
Vložnik je predlagal naslednjo trditev: „Glukoza prispeva k sproščanju energije pri presnovi.“
KG, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to glucose and contribution to energy-yielding metabolism (Question No EFSA-Q-2012-00270) [6].
Družba Dextro Energy GmbH & Co.
The claim proposed by the applicant was worded as follows: ‘Glucose contributes to normal muscle function’.
KG je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z glukozo in prispevanjem k sproščanju energije pri presnovi (vprašanje št.
Authorisation may also legitimately be withheld if health claims do not comply with other general and specific requirements of Regulation (EC) No 1924/2006, even in the case of a favourable scientific assessment by the Authority.
Vložnik je predlagal naslednjo trditev: „Glukoza prispeva k sproščanju energije pri presnovi med telesno vadbo.“
Health claims inconsistent with generally accepted nutrition and health principles should not be made.
Družba Dextro Energy GmbH & Co.